Skip to content

Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study

Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study - CAZ_AVI_BILE

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023533
Enrollment
12
Registered
2020-11-09
Start date
2021-08-04
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A04 K83.0

Interventions

Group 1: Preoperative administration (2h continuously) of Ceftazidime/Avibactam and perioperative measurement of antibiotic concentration in blood and bile

Sponsors

Universitätsklinikum Knappschaftskrankenhaus Bochum Klinik für Anästhesiologie, Intensivmedizin und Schmerzmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Male or female patients / 18 to 64 years of age / Patient requiring cholecystectomy because of cholecystitis or cholecystolithiasis or other elective abdominal surgery

Exclusion criteria

Exclusion criteria: Treatment with investigational drug within 28 days prior to start of study medication / Contra-indication for a perioperative antibiotic prophylaxis according to the standard in-house regimen (e.g. cholecystectomy with perforation of gallbladder) / Any medication considered relevant for proper performance of the study at the discretion of the investigator / Sepsis / Severe hepatitis or severe hepatic dysfunction / Renal impairment with need of renal replacement therapy / Pregnancy or lactation / Any disease considered relevant for proper performance of the study, or risks to the patient, at the discretion of the investigator. Explicitly an icterus, cholestasis, cholangitis, cholecytitis, hepatitis, congested liver, allergies, Clostridioides-difficile infection, relevant concomitant medication (e.g. metformin, ursodeoxycholic acid, statins) must be considered / No written informed consent

Design outcomes

Primary

MeasureTime frame
Bile CAZ/AVI concentrations at 2h±1h (n=4), 4h±1h (n=4), and 8h±1h (n=4) after continuous intravenous infusion over 2 hours.

Secondary

MeasureTime frame
Plasma CAZ/AVI concentrations at baseline and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7,h and 8h after CAZ/AVI infusion. Key pharmacokinetic parameters of CAZ/AVI in plasma and bile fluid.

Countries

Germany

Contacts

Public ContactTim Rahmel

Universitätsklinikum Knappschaftskrankenhaus Bochum Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie

Tim.Rahmel@kk-bochum.de00492342993001

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026